Citation Impact
Citing Papers
ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation
2009 StandoutScience
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
A Small-Molecule Modulator of Poly-α2,8-Sialic Acid Expression on Cultured Neurons and Tumor Cells
2001 StandoutScienceNobel
Diversification, not use, of the immunoglobulin VH gene repertoire is restricted in DiGeorge syndrome.
1993 StandoutNobel
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
1998
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
1999
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer statistics, 2019
2019 Standout
Multidrug resistance: molecular mechanisms and clinical relevance
1997
Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance
1997
MYC on the Path to Cancer
2012 Standout
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
2008 StandoutNature
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
1994
Global Cancer Statistics, 2002
2005 Standout
Early Identification of Refractory Epilepsy
2000 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
From amplification to function: the case of the MDR1 gene
1992
Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation
2010
Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
1993 Standout
Epigenetic regulation of normal and malignant hematopoiesis
2007
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
1995
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
1997
Lymphangiogenesis: Molecular Mechanisms and Future Promise
2010 Standout
Molecular characterization of eukaryotic polysialyltransferase-1
1995 Nature
Local Surgical, Ablative, and Radiation Treatment of Metastases
2009
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population‐based cohort of elderly patients with non‐Hodgkin lymphoma
2008
Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?
2011
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
The Hallmarks of Cancer
2000 Standout
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
2011
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Tumor-Induced Lymph Flow
2008
Treatment of Non-Hodgkin's Lymphoma
1993
Modulation of multidrug-resistant multiple myeloma by cyclosporin
1992
The neural cell adhesion molecule NCAM in multiple myeloma
1996
The CD5 B Cell
1989
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Non-Hodgkin's Lymphomas
2002
Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
1995
The biology of the P-glycoproteins
1995
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
2008
Echinocandin antifungal drugs
2003 Standout
Helicobacter pylori Infection and Gastric Lymphoma
1994 Standout
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma
2002
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Clinical trials of p-glycoprotein reversal in solid tumours
1996
Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
1997
Hematopoietic Stem-Cell Transplantation
2006 Standout
P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.
1996
GlcNAc 2-Epimerase Can Serve a Catabolic Role in Sialic Acid Metabolism
2003 StandoutNobel
Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
2001
P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy
1997
Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2
2014
Polysialic acid facilitates tumor invasion by glioma cells
2005
Primary brain tumours in adults
2012 Standout
Sarcoid reaction: a rare occurrence associated to colon adenocarcinoma (case report and literature review)
2016
Pancreatic Cancer
2010 Standout
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
1993
Mechanisms of Bone Metastasis
2004 Standout
MHC antigens and tumor escape from immune surveillance
2001
Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein
2001
ROS and the DNA damage response in cancer
2018 Standout
Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation†
2005
P-glycoprotein, multidrug resistance and tumor progression
1994
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
1995
Immunophenotyping in the management of gastric lymphoma
1991
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
2003
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
2001
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
1997
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
1999
State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma
2005
Polysialic Acid, a Glycan with Highly Restricted Expression, Is Found on Human and Murine Leukocytes and Modulates Immune Responses
2008 StandoutNobel
Effects of Isoprenoid Analogues ofSDB-Ethylenediamine on Multidrug Resistant Tumor Cells Alone and in Combination with Chemotherapeutic Drugs
2002
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
1999
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
1999
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Clinical Studies with Modulators of Multidrug Resistance
1995
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
1997
Nonviral Vectors for Gene Delivery
2008 Standout
Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments
2002
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
2000
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study
1996
Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
2012
Mechanisms of Cancer Drug Resistance
2002 Standout
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
1994
Spermidine in health and disease
2018 StandoutScience
Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin
1995
Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
2015
P-glycoprotein expression and function in circulating blood cells from normal volunteers
1994
Cancer treatment and survivorship statistics, 2016
2016 Standout
A novel membrane antigen selectively expressed on terminally differentiated human B cells
1994
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
2004
Cancer treatment and survivorship statistics, 2019
2019 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
2001
Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans
2000
A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
1998 StandoutNobel
Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma
2000
P-glycoprotein expression during tumor progression in the rat liver.
1992
Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
1997
Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study
2001
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
2001
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
1992
Polysialic acid governs T-cell development by regulating progenitor access to the thymus
2009 StandoutNobel
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia
2000
Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma
2000
Mammalian cytidine 5′-monophosphate N -acetylneuraminic acid synthetase: A nuclear protein with evolutionarily conserved structural motifs
1998
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
1992
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
2007
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Catherine Spier being referenced
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
2015
Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype
1991
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment
2012
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
1993
NCAM (CD56)-Positive Malignant Lymphoma
1993
HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.
1988
Generation of cytotoxic effector cells against human melanoma
1995
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
1991
Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma
1998
Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19)
1990
Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.
1993
Immunophenotypes in “well-differentiated” lymphoproliferative disorders, with emphasis on small lymphocytic lymphoma
1986
The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma.
1988
Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies.
1990
Ioachim's Lymph Node Pathology
2003
Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).
2004
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
2014
Myelomonocytic myeloma cell line (LB 84-1)
1989
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
2001
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures
2005